- Home
- Clinical Trials
- Combined Oral and IV Chemotherapy for Advanced or Metastatic Solid Tumors
Combined Oral and IV Chemotherapy for Advanced or Metastatic Solid Tumors
- Trial ID:
- IRB-20-7498
- Sonia Ali, MD
Inclusion Criteria
- Be 18 years of age or older
- Have a confirmed diagnosis of a locally advanced or metastatic solid tumor
- Be eligible to receive paclitaxel chemotherapy
- Have cancer that has progressed, despite standard therapies
- Agree to contraception requirements through 120 days following last dose
- Meet all other eligibility criteria
Exclusion Criteria
- Have received prior systemic anti-cancer treatment within 28 days
- Be pregnant or lactating, or expecting to conceive or father children within the defined study duration
- Have other significant medical conditions that would interfere with the study, in the physician’s opinion
Additional Info
- Rebastinib is an inhibitor of a molecule that acts in cancer growth and cancer cell survival, called “TIE2”. Paclitaxel is approved by the FDA as single therapy and in combination with other chemotherapy medications in a variety of cancer types. The dosage of rebastinib being administered is based on safety data from the prior cohorts of patients in part 1b of this study.
- Rebastinib will be taken orally twice daily. Paclitaxel will be given intravenously in the clinic on Days 1, 8, and 15 of each 28 day cycle.
- Patients will receive study treatment until they develop progressive disease, experience unacceptable toxicity, or withdraw from the study.
Contact Info:
- Clinical Research Services
- CRSLeadership@scriphealth.org